Interpreting numbers – more tricky bits

Slides:



Advertisements
Similar presentations
Causality Causality Hill’s Criteria Cross sectional studies.
Advertisements

Causality Inferences. Objectives: 1. To understand the concept of risk factors and outcome in a scientific way. 2. To understand and comprehend each and.
1 Case-Control Study Design Two groups are selected, one of people with the disease (cases), and the other of people with the same general characteristics.
Unit 14: Measures of Public Health Impact.
Public Health Perspective on Radon Control in Ireland Dr. Ina Kelly Specialist Registrar in Public Health Medicine Health Service Executive Department.
Chance, bias and confounding
Screening revision! By Ilona Blee. What are some UK Screening programmes?  Antenatal & newborn screening  Newborn Blood Spot  Newborn Hearing Screening.
Are exposures associated with disease?
Interpreting numbers ScotPHO training course March 2011 Dr Gerry McCartney Head of Public Health Observatory Division NHS Health Scotland
INTRODUCTION TO EPIDEMIOLO FOR POME 105. Lesson 3: R H THEKISO:SENIOR PAT TIME LECTURER INE OF PRESENTATION 1.Epidemiologic measures of association 2.Study.
EPIB-591 Screening Jean-François Boivin 29 September
Interpreting numbers – more tricky bits ScotPHO training course March 2011 Dr Gerry McCartney Head of Public Health Observatory Division NHS Health Scotland.
Lecture 6 Objective 16. Describe the elements of design of observational studies: (current) cohort studies (longitudinal studies). Discuss the advantages.
Measures of Association
ANALYTICAL STUDIES Prospective Studies COHORT Prepared by: Dr. Sahar Sabbour Community Medicine Department.
Lung Cancer Molecular Pathology of Cancer Boot Camp January 4, 2012 Jennifer Rider, ScD.
A short introduction to epidemiology Chapter 10: Interpretation Neil Pearce Centre for Public Health Research Massey University, Wellington, New Zealand.
Nies and Nies and McEwen: Chapter 4: ATI: Chapter 3 Epidemiology.
 Volunteer bias  Lead time bias  Length bias  Stage migration bias  Pseudodisease.
Screening Puja Myles
Measures of Disease Frequency, Effect and Impact Lecture by: Dr Amna Rehana Siddiqui Associate Professor Department of Family & Community Medicine September.
Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Showing Cause, Introduction to Study Design Principles of Epidemiology.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
What are the Chances Dr? Nick Pendleton. Can I have a Prostate Check? ?
Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Investigation 2-4 Backpacks and Back Pain Detectives in the Classroom - Investigation 2-4: Backpacks and Back Pain Is there an association between the.
Rates and Measurements Dr Hidayathulla Shaikh. Objectives At the end of the lecture students should be able to Discuss incidence Discuss prevalence Explain.
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M
Cancer prevention and early detection
Cancer prevention and early detection
Relative and Attributable Risks
Quality issues in monitoring diagnostic and treatment performance Dr
Study Designs Group Work
Present: Disease Past: Exposure
Comparison of three Observational Analytical strategies
Lecture notes on epidemiological studies for undergraduates
Principles of Epidemiology E
CASE-CONTROL STUDIES Ass.Prof. Dr Faris Al-Lami MB,ChB MSc PhD FFPH
Epidemiology 503 Confounding.
بسم الله الرحمن الرحيم COHORT STUDIES.
Showing Cause, Introduction to Study Design
Dr. Tauseef Ismail Assistant Professor Dept of C Med. KGMC
How do we delay disease progress once it has started?
How do we judge efficacy of a screening test?
Public Health Phase 3A Abigail Aitken
Diagnosis II Dr. Brent E. Faught, Ph.D. Assistant Professor
Public Health Phase 3A Abby Aitken -
Local Tobacco Control Profiles The webinar will start at 1pm
Dr. Hannah Jordan Lecturer in Public Health ScHARR
Epidemiology MPH 531 Analytic Epidemiology Case control studies
Measurements of Risk & Association …
Evaluating Effect Measure Modification
Review – Key Chapters Chapter 2 Chapter 3 Chapter 5 Chapter 6
Critical Appraisal วิจารณญาณ
Measures of risk and association
Challenges in Evaluating Screening & Prevention Interventions
Dr Luis E Cuevas – LSTM Julia Critchley
RISK ASSESSMENT, Association and causation
Risk Ratio A risk ratio, or relative risk, compares the risk of some health-related event such as disease or death in two groups. The two groups are typically.
Measures of Disease Frequency, Effect and Impact
Effect Modifiers.
Basic statistics.
BMTRY 736 Foundation of Epidemiology Fall 2019
Presentation transcript:

Interpreting numbers – more tricky bits ScotPHO training course March 2011 Dr Gerry McCartney Head of Public Health Observatory Division NHS Health Scotland gmccartney@nhs.net

Content More on causality Attributable fractions Screening – pitfalls to watch out for

Does A cause B? A B A B A C B A ? B

Factors which make causality more likely Bradford-Hill criteria Strength of association Consistency Specificity Temporality Biological gradient Plausibility Coherence Experiment Analogy

Does coffee cause ischaemic heart disease?

Effect modifiers Factors that do not lie on the causal pathway but which influence the magnitude of effect Male gender (effect modifier) Smoking Ischaemic heart disease

Necessary or sufficient causes? Asbestos exposure Asbestosis Smoking Lung cancer Jumping from plane without parachute Squished onto ground

Attributable fractions/risk “What fraction of disease incidence in the exposed group is attributable to the risk factor?” Calculated by taking the relative risk in an unexposed group from the relative risk in an exposed group

Attributable fractions Lung cancer deaths per 1,000 population per year Coronary heart disease deaths per 1,000 per year Heavy smokers 166 599 Non-smokers 7 422

Attributable fractions Lung cancer deaths per 1,000 population per year Coronary heart disease deaths per 1,000 per year Heavy smokers 166 599 Non-smokers 7 422 Excess risk of heavy smoking 166 – 7 = 159 599 – 422 = 177

Attributable fractions Lung cancer deaths per 1,000 population per year Coronary heart disease deaths per 1,000 per year Heavy smokers 166 599 Non-smokers 7 422 Excess risk of heavy smoking 166 – 7 = 159 599 – 422 = 177 Attributable risk of heavy smoking 159 / 166 = 95.8% 177 / 599 = 29.5%

Attributable fractions/risk Attributable fractions can also be applied to the whole population using the formula: = (risk in total population – risk in unexposed population) / risk in total population

Screening Why do we screen for conditions? When is screening appropriate? Problems with evaluation of screening programmes Particular biases

Why screen for conditions? To improve outcomes for individuals Keep Well health checks Breast mammography To improve outcomes for populations Port health checks Employment checks

When should you screen? Based on the Wilson – Junger criteria: Is there an effective intervention? Does earlier intervention improve outcomes? Is there a screening test which recognises disease earlier than usual? Is the test available and acceptable to the target population? Is the disease a priority? Do the benefits outweigh the costs?

Screening – why is it different? Individuals may not benefit Involves people who are well subjecting themselves to testing – medicalisation Creation of a pre-disease state False positive tests False negative tests Initiated by health professionals not individuals Cost-benefit depends on prevalence within a population Inequalities implications

Particular biases Lead time bias Given that screening picks up disease at an earlier stage – the time between diagnosis and death increases without any actual increase in survival Symptoms Death Death Detected by screening

Length time bias Screening is more likely to detect less aggressive disease and therefore can give impression of improved survival X X X X X X X

Measures used in screening Sensitivity is the likelihood that those with disease will be picked up by the screening test Specificity is the likelihood that those with a negative screening test will not have the disease Positive predictive value is the likelihood that those with a positive test will have the disease Negative predictive value is the likelihood that those with a negative test will not have the disease

Measures for screening Sensitivity and Specificity Positive predictive value and Negative predictive value Disease Total Yes No Screening test Positive 300 30 130 Negative 20 3000 3020 320 3030 3350

Measures for screening Sensitivity and Specificity Positive predictive value and Negative predictive value Disease Total Yes No Screening test Positive 300 30 130 Negative 20 3000 3020 320 3030 3350 Sensitivity = 300/320 = 94% Specificity = 3000/3030 = 99% PPV = 300/330 = 91% NPV = 3000/3020 = 99%

Summary Bradford-Hill criteria can be used to judge whether an association is likely to be causal Attributable fractions can help identify the discrete contribution of particular risks to an outcome Screening is different to other medical interventions and can cause harm Screening evaluations have their own potential biases – lead time and length time bias

Questions gmccartney@nhs.net